http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013147022-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2602-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C307-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C209-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D291-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0406 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-41 |
| filingDate | 2012-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013147022-A |
| titleOfInvention | COMPOUNDS FOR THE USE OF VISUALIZATION, DIAGNOSTICS AND / OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
| abstract | 1. The compound of formula I in which (R) (Q) (R) is selected from the group consisting of (O) (bond) (S (O)), ([F] fluorine) (void) (S (O) (O ) (X)), (F) (void) (S (O) (O) X)), ([F] fluorine) (void) (H), and (F) (void) (H); Choose from a group consisting of Li, Na, K, Cs, and / or Rb; a bond means that the atoms or groups of atoms adjacent to the bond collectivize at least one pair of electrons and thus chemically bind to each other; void means that not there is a chemical bond with either an atom or a group of atoms that binds R and R, including all isomeric forms of the specified compound, including but not limited to In summary, enantiomers and diastereoisomers, as well as mixtures of isomers, and any pharmaceutically acceptable salt thereof. 2. A compound according to claim 1, characterized in that the compound is selected from a compound of formula Ia, including all isomeric forms of the compound, including, but not limited to, enantiomers and diastereoisomers, as well as mixtures of isomers, and any pharmaceutically acceptable salt thereof. A compound according to claim 2, characterized in that the compound is (1S, 2S) -2- [F] fluoro-N [(1,1-H) prop-2-yn-1-yl] indan-1-amine including any pharmaceutically acceptable salt thereof. 4. A compound according to claim 1, characterized in that the compound is selected from a compound of formula Ib including all isomeric forms of said compound, including, but not limited to, enantiomers and diastereoisomers, as well as mixtures of isomers, and any pharmaceutically acceptable salt thereof. A compound according to claim 4, characterized in that the compound is (1S, 2S) -2-fluoro-N - [(1,1-H) prop-2-yn-1-yl] indan-1-amine, including any pharmaceutically acceptable salt. 6. A compound according to claim 1, characterized in that the compound is selected from a compound of formula Ic including all isomeric forms indicated |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2799448-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2727568-C2 |
| priorityDate | 2011-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.